

What is the QUINTESSENTIAL-2 Study testing?

This study is testing an investigational therapy in adults with multiple myeloma whose cancer has progressed or returned after treatment (relapsed/refractory).

Researchers want to:

- Better understand if the study therapy works and is safe.
- Compare the effects of the study therapy with standard treatment for your type of multiple myeloma.

You may be eligible if you:

- Are 18 years of age or older.
- Have multiple myeloma that has progressed during or after your last treatment.
- Have received 1 to 3 treatments for multiple myeloma.

There are also additional requirements. The study doctor will explain these to you.

Thank you for your interest in the QUINTESSENTIAL-2 Study.

Clinical studies help doctors find new ways to treat medical conditions. These studies explore whether a study drug works safely in people with that condition.

You may or may not directly benefit from being in this study. Information learned through your participation may help others with multiple myeloma in the future.

Being in a clinical study is voluntary. If you decide to join and then change your mind, you can leave at any time.

To learn more about clinical studies for multiple myeloma, visit: bms.sparkcures.com.

If you are interested in learning more about the QUINTESSENTIAL-2 Study, please contact the study team at:



The QUINTESSENTIAL-2 Study

A clinical study for adults with multiple myeloma that has progressed or returned after treatment

Study Overview



What is the study therapy?

The study therapy is a type of chimeric antigen receptor (CAR) T-cell therapy. CAR T-cell therapy is an immunotherapy that programs your T cells (a type of immune cell) to better fight cancer cells.

CAR T-cell therapy has multiple steps that include:

1. Collecting your white blood cells (immune cells).
2. Making the study therapy by programming your T cells in a lab to target a specific marker on myeloma cells. During this time, you will receive standard treatment for multiple myeloma.
3. Chemotherapy to prepare your body for the study therapy.
4. A one-time infusion of the study therapy.

The study doctor will explain this process in more detail.

What happens during the study?

The study is divided into 3 periods. How long you are in the study and how many visits you have depend on the study treatment you are assigned to.

Screening Period

To see if you qualify, you will answer questions about your health and have tests.

Study Treatment Period

If you qualify, you will be randomly placed into a group (like a flip of a coin) to receive:

- a. The study therapy as a one-time dose **OR**
- b. Standard treatment for multiple myeloma until your cancer progresses.

You will also have visits with health checks and tests.

Follow-up Period

After you complete the Study Treatment Period, you'll have additional visits to check on your health.

What tests will I have during the study?

Below are some tests you will have at study visits. Not all tests will be performed at each visit. Talk to the study doctor for more information.



Physical exam



Neurological exam



Vital signs



Heart activity (ECG)



Heart imaging (Echo, MUGA scan)



Bone imaging



Body imaging (CT/MRI/PET scan, if needed)



Blood tests



Bone marrow sample



Urine test



Questionnaires

CT = computed tomography; ECG = electrocardiogram; Echo = echocardiogram; MRI = magnetic resonance imaging; MUGA = multigated acquisition; PET = positron emission tomography.